Float Short %

11.73

Margin Of Safety %

Put/Call OI Ratio

0.09

EPS Next Q Diff

0.53

EPS Last/This Y

0.37

EPS This/Next Y

0.55

Price

6.58

Target Price

17.22

Analyst Recom

1.2

Performance Q

25.57

Relative Volume

1.3

Beta

1.39

Ticker: VIR

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	VIR	5.38	0.15	0.00	9258
2025-11-11	VIR	5.72	0.15	0.01	9061
2025-11-12	VIR	5.71	0.15	0.45	9488
2025-11-13	VIR	5.48	0.14	0.11	9364
2025-11-14	VIR	5.64	0.15	0.00	9370
2025-11-17	VIR	5.49	0.14	0.78	9482
2025-11-18	VIR	5.51	0.14	0.59	9563
2025-11-19	VIR	5.43	0.14	0.26	9580
2025-11-20	VIR	5.55	0.15	0.00	9569
2025-11-21	VIR	5.68	0.14	0.13	9821
2025-11-24	VIR	6.12	0.10	0.03	7485
2025-11-25	VIR	6.45	0.09	0.00	9171
2025-11-26	VIR	6.41	0.08	0.00	10302
2025-12-01	VIR	6.07	0.07	0.17	10581
2025-12-02	VIR	5.64	0.10	0.03	12526
2025-12-03	VIR	6.26	0.10	0.01	13523
2025-12-04	VIR	6.78	0.10	0.01	13282
2025-12-05	VIR	6.5	0.08	0.02	15317
2025-12-08	VIR	6.57	0.09	0.02	15016
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	VIR	5.37	44.8	-	-3.26
2025-11-11	VIR	5.71	44.8	-	-3.26
2025-11-12	VIR	5.72	44.8	-	-3.26
2025-11-13	VIR	5.48	44.8	-	-3.26
2025-11-14	VIR	5.65	7.5	-	-3.47
2025-11-17	VIR	5.50	19.5	-	-3.47
2025-11-18	VIR	5.52	19.5	-	-3.47
2025-11-19	VIR	5.44	19.5	-	-3.47
2025-11-20	VIR	5.56	19.5	-	-3.47
2025-11-21	VIR	5.68	16.9	-	-3.47
2025-11-24	VIR	6.12	16.9	-	-3.47
2025-11-25	VIR	6.44	16.9	-	-3.47
2025-11-26	VIR	6.41	16.9	-	-3.47
2025-12-01	VIR	6.07	17.1	-	-3.46
2025-12-02	VIR	5.63	17.1	-	-3.46
2025-12-03	VIR	6.27	17.1	-	-3.46
2025-12-04	VIR	6.77	17.1	-	-3.46
2025-12-05	VIR	6.50	17.1	-	-3.46
2025-12-08	VIR	6.58	17.1	-	-3.46
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	VIR	-4.60	2.20	11.80
2025-11-11	VIR	-4.60	2.20	11.80
2025-11-12	VIR	-4.60	2.20	10.34
2025-11-13	VIR	-4.60	2.20	10.34
2025-11-14	VIR	-4.60	2.20	10.34
2025-11-17	VIR	-4.60	2.59	10.29
2025-11-18	VIR	-4.65	2.59	10.29
2025-11-19	VIR	-4.65	2.59	10.29
2025-11-20	VIR	-4.65	2.59	10.29
2025-11-21	VIR	-4.65	2.59	10.29
2025-11-24	VIR	-4.65	-2.88	10.29
2025-11-25	VIR	-4.65	-2.88	10.29
2025-11-26	VIR	-5.56	-2.88	11.81
2025-12-01	VIR	-5.92	-2.85	11.75
2025-12-02	VIR	-5.98	-2.85	11.75
2025-12-03	VIR	-6.39	-2.85	11.75
2025-12-04	VIR	-6.39	-2.85	11.75
2025-12-05	VIR	-6.39	-2.85	11.75
2025-12-08	VIR	-6.39	-2.89	11.73
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-1.17

Avg. EPS Est. Current Quarter

-0.63

Avg. EPS Est. Next Quarter

-0.64

Insider Transactions

-6.39

Institutional Transactions

-2.89

Beta

1.39

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

95.3

Max Drawdown 5-Year %

-94.8

Target Price

17.22

P/E

Forward P/E

PEG

P/S

54.3

P/B

1.15

P/Free Cash Flow

EPS

-3.62

Average EPS Est. Cur. Y

-3.46

EPS Next Y. (Est.)

-2.92

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-2963.54

Relative Volume

1.3

Return on Equity vs Sector %

-89.6

Return on Equity vs Industry %

-74.7

EPS 1 7Days Diff

-0.2

EPS 1 30Days Diff

-0.2

EBIT Estimation

Vir Biotechnology, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 408

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

stock quote shares VIR – Vir Biotechnology, Inc. Stock Price stock today

news today VIR – Vir Biotechnology, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch VIR – Vir Biotechnology, Inc. yahoo finance google finance

stock history VIR – Vir Biotechnology, Inc. invest stock market

stock prices VIR premarket after hours

ticker VIR fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: VIR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y